ACROFAN

Global Pharmaceutical R&D Directory 2022: Trends in Global R&D Investment, Cost and Culture - ResearchAndMarkets.com

Published : Thursday, December 30, 2021, 2:14 am
ACROFAN=Businesswire | webmaster@businesswire.com | SNS

DUBLIN--(BUSINESS WIRE)--The "Global Pharmaceutical R & D Directory 2022" directory has been added to ResearchAndMarkets.com's offering.


The Global Pharmaceutical R&D Directory provides a wealth of key business data on trends in pharmaceutical research. At a time when investment in R&D is at an all time high, this publication is intended as a strategic reference guide to the important trends in pharmaceutical R&D, as well as providing the means to benchmark your company's performance.

From an examination of global R&D investment and productivity to a breakdown of R&D trends in every major therapeutic class, the R&D Directory provides a comprehensive review of the current R&D environment.

The R&D Directory provides time-saving business information on:

  • The development pipeline of major companies analyzed by therapeutic categories and stages
  • Compounds in research by therapeutic class for major companies
  • Number of licensed compounds by therapeutic class and development stage
  • Comparison of companies' licensed/originated product pipelines
  • Average development time to market, and attrition data
  • Trends in global R&D investment, cost and culture
  • Number of biotechnology products by development phase, therapeutic class and type

Key Features:

  • Trends in licensing for major pharmaceutical companies
  • R&D Focus for key therapy areas
  • Benchmark development time by phase and success for over dozens of therapeutic categories
  • Comparisons of compounds in research by development stage for dozens of therapeutic areas
  • Analysis of previous year's pipeline development by stage for all major pharmaceutical companies worldwide

Contents

  • Section 1 & 2 of The R&D Directory look at the trends in R&D expenditure in the major markets, changes in employment patterns and productivity levels in relation to pharmaceutical sales.
  • Section 3 reviews the outsourcing industry and examines its role in pharmaceutical R&D.
  • Section 4 to 9 analyses the trends in R&D by examining the therapeutic focus of selected companies, preclinical compounds, biotechnology compounds, compounds in clinical development for every major therapy class, and licensing activities.
  • Section 10 provides extensive attrition and time-in-development data for the major therapeutic categories.

Coverage:

  • Western & Eastern Europe incl. UK
  • USA & Canada
  • South & Central America
  • The Middle East
  • All of Africa
  • All of Asia, including China, India and Japan
  • Australia & New Zealand

Based on primary research, the 2-volume The R&D Directory provides the most comprehensive assessment of R&D available! Packed with facts, personalities, charts and statistics, it is presented as a book and also as a fully searchable PDF edition and CD-ROM.

For more information about this directory visit https://www.researchandmarkets.com/r/h5md6x

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900



Copyright © acrofan/Business Wire All Right Reserved


    Acrofan     |     Contact Us : guide@acrofan.com     |     Contents API : RSS

Copyright © Acrofan All Right Reserved